Nanologica AB (publ) (Nanologica AB) aksje

Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides; NLAB Idun SP, a strong cation exchanger with sulfopropyl groups as ligands; NLAB Idun Q, a strong anion exchanger with a quaternary amine ligand; and NLAB Siv, a non-silica-based media for purification by preparative chromatography used for products outside the peptide range. It also provides high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces; and analytical chromatography, an analysis method in the pharmaceutical and food industries. The company's products are used to purify substances with a focus on peptide drugs for the treatment of diabetes and obesity. It serves pharmaceutical companies, as well as contract manufactures of insulin and insulin analogues, GLP-1 analogues, biosimilars to insulin and GLP-1 analogues, and other peptide drugs. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.